Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis.

  • 2007-07
  • Thyroid : official journal of the American Thyroid Association 17(7)
    • Elias E Mazokopakis
    • John A Papadakis
    • Maria G Papadomanolaki
    • Antony G Batistakis
    • Triantafillos G Giannakopoulos
    • Eftichios E Protopapadakis
    • Emmanuel S Ganotakis

Study Design

Type
Clinical Trial
Sample size
n = 80
Population
80 women with Hashimoto's thyroiditis, median age 37 (range 24-52) years
Methods
Prospective study; all patients received 200 microg Se as l-selenomethionine orally for 6 months; then 40 continued Se (Group A) and 40 stopped (Group B); followed for 1 year with measurements every 3 months
Duration
1 year
Funding
Unclear

Objective

We studied the effects of selenium (Se) treatment on serum anti-thyroid peroxidase (TPO) levels in Greek patients with Hashimoto's thyroiditis (HT).

Design

We prospectively studied 80 women with HT, median age 37 (range 24-52) years, for 1 year. All patients received 200 microg Se in the form of l-selenomethionine orally for 6 months. At the end of the 6-month period, 40 patients continued taking 200 microg Se (Group A) and 40 patients stopped (Group B). Serum thyrotropin (TSH), free triiodothyronine (FT(3)), free thyroxine (FT(4)), anti-TPO, and anti-thyroglobulin (Tg) levels were measured at baseline and at the end of each 3-month period.

Main outcome

There was a significant reduction of serum anti-TPO levels during the first 6 months (by 5.6% and 9.9% at 3 and 6 months, respectively). An overall reduction of 21% (p < 0.0001) compared with the basal values was noted in Group A. In Group B, serum anti-TPO levels were increased by 4.8% (p < 0.0001) during the second 6-month period.

Conclusions

Our study showed that in HT patients 6 months of Se treatment caused a significant decrease in serum anti-TPO levels, which was more profound in the second trimester. The extension of Se supplementation for 6 more months resulted in an additional 8% decrease, while the cessation caused a 4.8% increase, in the anti-TPO concentrations.

Research Insights

  • In Group B, serum anti-TPO levels were increased by 4.8% (p < 0.0001) during the second 6-month period.

    Effect
    Neutral
    Effect size
    Small
    Dose
    200 microg Se in the form of l-selenomethionine orally for 6 months, then cessation for 6 months
  • There was a significant reduction of serum anti-TPO levels during the first 6 months (by 5.6% and 9.9% at 3 and 6 months, respectively). An overall reduction of 21% (p < 0.0001) compared with the basal values was noted in Group A.

    Effect
    Beneficial
    Effect size
    Moderate
    Dose
    200 microg Se in the form of l-selenomethionine orally for 6 months
Back to top